# Psoriasis

Manage psoriasis by confirming the clinical phenotype, quantifying extent and life impact, identifying psoriatic arthritis and cardiometabolic comorbidity, then selecting site-directed topical therapy, phototherapy, systemic therapy, or biologic treatment according to severity, trajectory, and treatment risk.

**Clinical question:** How should physicians assess psoriasis severity, select treatment intensity, and screen for consequential comorbid disease?

Updated: 2026-09-15T23:43:41.110253+00:00

## What matters in practice
- Diagnosis is usually clinical; biopsy is most useful for atypical morphology, diagnostic uncertainty, pustular disease, or erythroderma. [2][15][16]
- Record BSA, PASI or PGA, and quality-of-life impact at baseline; BSA greater than 10%, PASI greater than 10, or DLQI greater than 10 identifies a commonly used moderate-to-severe threshold for systemic-treatment consideration. [5][14][15][17]
- Use topical corticosteroids and/or vitamin D analogues for mild or limited disease, while extensive, refractory, or high-impact disease warrants phototherapy or systemic treatment selection. [1][2][7][9]
- Ask specifically about inflammatory musculoskeletal symptoms and examine for nail disease, dactylitis, enthesitis, and swollen joints; suspected psoriatic arthritis requires rheumatology-directed assessment because persistent inflammatory disease can be disabling. [1][24]
- Before biologic treatment, perform a focused infection history and screen for latent tuberculosis; treatment should be withheld during major infection. [11][12]

## Confirm psoriasis clinically and identify presentations requiring urgent escalation

Most plaque psoriasis does not require laboratory confirmation.

Make the diagnosis clinically when sharply demarcated scaly plaques have a typical symmetric distribution involving scalp, extensor elbows or knees, lumbosacral skin, or flexures. Document morphology and distribution before treatment because plaque psoriasis accounts for approximately 80% to 90% of cases and may coexist with nail or fold disease that changes topical formulation and potency selection. [16][17]

Obtain a skin biopsy when the morphology or distribution is atypical, when an alternative papulosquamous disorder remains plausible, or when erythrodermic or pustular disease creates diagnostic uncertainty. Histopathology can complement the clinical diagnosis but is not routine for characteristic plaque psoriasis. [15][16]

Treat generalized erythroderma as an urgent dermatologic presentation. It may arise from progressive confluent plaque disease or unstable psoriasis precipitated by infection, medications, or corticosteroid withdrawal, and can cause hypothermia, hypoalbuminemia, anemia, and nutrient loss. [15] Evaluate for precipitating infection or medication exposure and arrange urgent specialty management rather than escalating outpatient topical therapy alone. [15]
- At each flare, review potential exacerbating factors: infection, alcohol, medications, stress, and intercurrent illness. [2]
- Document a trauma-associated distribution when present; new lesions at sites of injury support a Koebner phenomenon. [16]
- Refer promptly for atypical, pustular, erythrodermic, or extensive disease and for failure of systemic or biologic therapy. [14]

*Clinical findings that change diagnostic or disposition decisions. [14][15][16]*

| Finding | Interpretation | Next action |
| --- | --- | --- |
| Typical, symmetric, well-circumscribed scaly plaques | Clinical diagnosis is usually sufficient. [2][16] | Quantify severity and initiate site-appropriate treatment. [1][2] |
| Atypical morphology or persistent diagnostic uncertainty | Psoriasis may require histopathologic confirmation or exclusion of another dermatosis. [15][16] | Perform skin biopsy or refer to dermatology. [14][15] |
| Generalized exfoliative erythema | Possible erythrodermic psoriasis with thermoregulatory and metabolic complications. [15] | Urgent dermatology assessment; evaluate triggers and systemic complications. [15] |
| Pustular phenotype | Requires specialist assessment because it is not managed as routine stable plaque disease. [14] | Expedite dermatology evaluation. [14] |

## Measure extent, site burden, and quality-of-life impact before choosing therapy

Extent alone can underestimate high-impact localized disease.

Record BSA and a reproducible activity measure such as PASI or PGA at baseline and before changing treatment. PASI incorporates plaque erythema, induration, scaling, and involved surface area across the head and neck, trunk, and upper and lower limbs; PGA, BSA, DLQI, and nail scores can complement PASI when the disease phenotype or practice workflow makes PASI less practical. [15]

Use severity measures to guide, not replace, clinical judgment. A PASI of at least 10 or BSA of at least 10% with DLQI greater than 10 is a commonly used severe-disease threshold, while dermatology referral criteria also identify BSA greater than 10%, PASI greater than 10, or DLQI greater than 10 as moderate-to-severe disease. [5][14] Lesions on the scalp, face, flexures, hands, feet, genitals, or nails can justify escalation despite limited BSA when symptoms, function, or treatment feasibility are disproportionate. Site and symptom burden are explicit components of severity assessment. [15][17]

Use topical treatment for mild or limited psoriasis, particularly when disease can be treated reliably by the patient. Topical corticosteroids and vitamin D analogues are the core first-line options for limited disease. [1][2][7] If disease is extensive, cannot be practically treated with topical therapy, remains uncontrolled despite an adherent topical regimen, or produces substantial functional or quality-of-life burden, assess candidacy for phototherapy or systemic treatment. [7][9][14]
- Measure DLQI when visible, genital, hand-foot, scalp, or nail disease appears discordant with BSA; impact on daily life is part of severity determination. [15][17]
- Record nail involvement because it contributes to disease burden and should heighten surveillance for musculoskeletal disease. [15][24]
- Use serial BSA, PASI/PGA, and patient-reported impact to determine whether a treatment is controlling disease rather than relying on a single baseline category. [15][17]

*Practical escalation framework for cutaneous psoriasis. [1][2][5][7][9][14][15]*

| Clinical pattern | Assessment target | Management direction |
| --- | --- | --- |
| Limited plaque disease | Document BSA, symptomatic sites, and response to prior topical therapy. [1][15] | Use topical corticosteroid and/or vitamin D analogue therapy. [1][2] |
| High-impact localized disease | Assess affected site and DLQI even when BSA is low. [15][17] | Consider dermatology escalation when topical treatment is inadequate or impractical. [14] |
| Extensive or high-burden disease | BSA greater than 10%, PASI greater than 10, or DLQI greater than 10 supports moderate-to-severe classification. [5][14] | Consider phototherapy or systemic nonbiologic or biologic therapy through individualized selection. [7][9][13] |
| Refractory disease on systemic or biologic treatment | Reassess phenotype, adherence, safety, and comorbid inflammatory disease. [14][24] | Refer or re-engage dermatology; switching to another biologic is an accepted strategy after biologic failure. [8][9] |

## Match topical vehicle and escalation to body site and treatment feasibility

Topical therapy remains foundational for mild-to-moderate plaque disease.

For limited psoriasis, select a topical corticosteroid, a vitamin D analogue, or their combination according to lesion thickness, anatomic site, cosmetic acceptability, and ability to apply treatment consistently. AAD-NPF guidance addresses topical agents and severity measurement, and BMJ Best Practice identifies topical corticosteroids and/or vitamin D analogues as treatment for mild or limited disease. [1][7]

For scalp psoriasis, use topical therapy in a formulation the patient can apply through hair-bearing skin. When a potent corticosteroid or vitamin D analogue used for up to 8 weeks does not achieve clearance, near-clearance, or satisfactory control, an adult can receive a very potent corticosteroid up to twice daily for 2 weeks; coal tar once or twice daily and specialist support with application technique are alternatives. [19] Vitamin D analogue monotherapy is most appropriate when corticosteroids cannot be used at that site or for mild-to-moderate scalp disease. [19]

Move beyond topical monotherapy when distribution makes application burdensome or when objective activity and patient-reported burden remain unacceptable despite a coherent regimen. Phototherapy is addressed in AAD-NPF psoriasis guidance and is an appropriate treatment-domain consideration before or alongside systemic options based on disease extent, access, and patient preference. [2][7][14]
- Choose vehicle and regimen around the involved site; lesion location is a core determinant of treatment selection. [17]
- For scalp disease uncontrolled after the defined topical course, reassess adherence and formulation before declaring pharmacologic failure. [19]
- Use dermatology referral for phototherapy candidacy or when topical application support and alternative options are required. [14][19]

*Site- and response-based topical decisions. [1][7][19]*

| Scenario | Action | Escalation trigger |
| --- | --- | --- |
| Mild or limited plaque psoriasis | Topical corticosteroid and/or vitamin D analogue. [1][2] | Persistent activity or impractical topical treatment. [7][14] |
| Mild-to-moderate scalp psoriasis when corticosteroids cannot be used | Topical vitamin D analogue alone may be used. [19] | Inadequate control after up to 8 weeks of topical therapy. [19] |
| Adult scalp psoriasis uncontrolled after up to 8 weeks | Very potent corticosteroid up to twice daily for 2 weeks, or coal tar once or twice daily. [19] | Refer for application support or alternative therapy. [19] |

## Choose systemic or biologic therapy by disease burden, comorbidity, and safety constraints

Moderate-to-severe disease requires individualized risk-benefit selection.

For adults with moderate-to-severe psoriasis, AAD-NPF guidance supports methotrexate and apremilast as systemic nonbiologic options; methotrexate is less effective for cutaneous psoriasis than adalimumab and infliximab. [9] Cyclosporine and acitretin are also addressed within systemic nonbiologic treatment guidance. [13] Select among these approaches according to urgency of control, reproductive considerations, hepatic and renal risk, comorbid inflammatory disease, treatment burden, and monitoring capacity; the available guideline summary does not establish a universal sequence among systemic agents. [13][20]

Biologic therapy is a treatment option for adults with moderate-to-severe psoriasis, including TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibition, and IL-23 inhibitors. [9][11] After inadequate response to a first biologic, switching to a second biologic is a guideline-supported strategy; biologic plus methotrexate is another possible approach, although psoriasis-specific evidence for combination treatment is limited. [8]

Before initiating a biologic, obtain a focused infection history and physical examination and screen for latent tuberculosis infection. [11] Screen for viral infections, including HIV and hepatitis, before biologic therapy as described in psoriasis management recommendations; withhold biologic treatment during a major infection. [12] Incorporate inflammatory bowel disease, congestive heart failure, multiple sclerosis, hepatitis B, prior nonmelanoma skin cancer, lymphoma, and latent tuberculosis into biologic selection because these conditions materially alter class-specific risk assessment. [11]
- Use noninvasive hepatic-fibrosis assessment when monitoring methotrexate-associated hepatotoxicity, consistent with revised AAD-NPF monitoring guidance. [9]
- Do not continue biologic treatment through a major infection. [12]
- When biologic efficacy is inadequate, verify diagnosis, phenotype, adherence, safety, and joint disease before switching mechanism or agent. Switching to a second biologic is an accepted next step. [8][24]

### Interpreting infection risk during biologic treatment

Discuss infection risk in class- and patient-specific terms rather than treating all biologics as equivalent. In PSOLAR, serious-infection incidence was 0.83 per 100 patient-years with ustekinumab, 1.47 with etanercept, 1.97 with adalimumab, and 2.49 with infliximab; pneumonia and cellulitis were the most frequently reported serious infections. [11] These observational rates inform counseling but do not substitute for baseline infection screening or individualized selection.

*Systemic-treatment safety decisions supported by psoriasis guidance and observational safety data. [8][9][11][12][13]*

| Decision point | Action | What changes management |
| --- | --- | --- |
| Moderate-to-severe cutaneous disease | Consider methotrexate, apremilast, cyclosporine, acitretin, phototherapy, or biologic therapy according to patient factors. [7][9][13] | Comorbidities, reproductive risk, organ toxicity risk, access, and monitoring capacity determine selection. [11][13][20] |
| Before biologic initiation | Take infection history and perform examination; screen for latent tuberculosis and viral infections including HIV and hepatitis. [11][12] | Treat or otherwise address identified infection risk before immunomodulatory therapy. [11][12] |
| Major infection during biologic therapy | Withhold treatment. [12] | Resume only after the infection has been clinically addressed. [12] |
| Inadequate response to first biologic | Switch to a second biologic; combination with methotrexate is possible but supported by limited psoriasis-specific evidence. [8] | Reassess phenotype and comorbid conditions before choosing the next mechanism. [11][24] |

## Screen actively for psoriatic arthritis and cardiometabolic disease

Cutaneous control does not exclude clinically consequential systemic disease.

Screen for psoriatic arthritis at psoriasis visits by asking about inflammatory joint pain, prolonged stiffness, swollen digits, heel or other entheseal pain, back symptoms, and functional limitation; examine for swollen joints, dactylitis, enthesitis, and nail disease. Approximately 30% of patients with cutaneous psoriasis in dermatology clinics have rheumatologist-diagnosed psoriatic arthritis. [1] Refer suspected inflammatory musculoskeletal disease to rheumatology because psoriatic arthritis is potentially debilitating and requires targeted treatment with ongoing monitoring. [24]

Treat psoriasis as a multisystem disease and address cardiovascular risk factors rather than focusing only on plaque clearance. Psoriasis and psoriatic arthritis are epidemiologically linked to cardiovascular risk factors and increased cardiovascular disease risk, while psoriatic arthritis is associated with hypertension, metabolic syndrome, obesity, hyperlipidemia, diabetes mellitus, and cardiovascular disease. [9][23][24] Measure and manage blood pressure, weight, glycemic status, and lipids according to standard primary-care and cardiovascular-prevention pathways.

Ask about inflammatory bowel symptoms and ocular symptoms when musculoskeletal disease is present. Inflammatory bowel disease, particularly Crohn disease, is associated with increased risk of psoriatic arthritis, and uveitis requires ophthalmologic evaluation and treatment. [24] These findings should influence biologic-class selection and coordination with gastroenterology, rheumatology, or ophthalmology. [11][24]
- Trigger rheumatology referral for swollen joints, dactylitis, enthesitis, inflammatory axial symptoms, or persistent functional limitation suggestive of psoriatic arthritis. [24]
- In patients with psoriatic arthritis, screen for obesity, hypertension, dyslipidemia, diabetes, and cardiovascular disease. [24]
- Refer uveitis for ophthalmologic evaluation rather than managing ocular inflammation solely through dermatologic therapy. [24]

*Comorbidity findings that require a defined next step. [1][11][23][24]*

| Finding | Clinical implication | Next step |
| --- | --- | --- |
| Inflammatory joint symptoms, dactylitis, enthesitis, or swollen joints | Possible psoriatic arthritis with risk of persistent disabling inflammatory disease. [24] | Refer to rheumatology for diagnostic assessment and targeted management. [24] |
| Hypertension, obesity, dyslipidemia, diabetes, or metabolic syndrome | Higher cardiometabolic burden accompanies psoriasis and psoriatic arthritis. [23][24] | Measure and treat modifiable risk factors through standard cardiovascular prevention pathways. [23][24] |
| Inflammatory bowel disease or neurologic/cardiac comorbidity | May alter biologic risk-benefit selection. [11][24] | Coordinate treatment selection with the relevant specialty. [11] |
| Uveitis symptoms or diagnosis | Requires specialist ocular evaluation and treatment. [24] | Refer to ophthalmology. [24] |

## References
1. Psoriasis - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/74?locale=ar
2. Psoriasis - Symptoms, diagnosis and treatment | BMJ Best Practice — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-gb/74
3. Guidelines for the Diagnosis and Treatment of Psoriasis in China — journals.lww.com — https://journals.lww.com/ijdv/fulltext/2020/03000/guidelines_for_the_diagnosis_and_treatment_of.3.aspx
4. 22nd PANLAR Congress: Miami, FL, August 12-15 2020 : JCR - Ovid — journals.lww.com — https://journals.lww.com/jclinrheum/fulltext/2020/04001/22nd_panlar_congress__miami,_fl,_august_12_15_2020.1.aspx
5. Biologics and Biosimilars in Psoriasis : Indian Journal of Dermatology — journals.lww.com — https://journals.lww.com/ijd/fulltext/2023/68030/biologics_and_biosimilars_in_psoriasis.9.aspx
6. Systemic Management of Psoriasis Patients in Indian Scenario - Ovid — journals.lww.com — https://journals.lww.com/idoj/fulltext/2021/12050/systemic_management_of_psoriasis_patients_in.2.aspx
7. Psoriasis clinical guideline — staging.aad.org — https://staging.aad.org/member/clinical-quality/guidelines/psoriasis
8. Treatment Sequencing After Failure of the First Biologic in Cost-Effectiveness Models of Psoriasis: A Systematic Review of Published Models and Clinical Practice Guidelines - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC3964298
9. Psoriasis clinical guideline - American Academy of Dermatology — www.aad.org — https://www.aad.org/member/clinical-quality/guidelines/psoriasis
10. Risk of psoriasis in people with hidradenitis suppurativa: A systematic review and meta-analysis - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9752046
11. Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8051287
12. Recommendations for Management of Childhood Psoriasis - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8664175
13. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/32119894
14. Plaque Psoriasis - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK430879
15. [PDF] 29 October 2024 WHO Expert Committee on the Selection and Use ... — cdn.who.int — https://cdn.who.int/media/docs/default-source/2025-eml-expert-committee/addition-of-new-medicines/a.31_ustekinumab.pdf
16. 1. Application to Add Ustekinumab to the ... — cdn.who.int — https://cdn.who.int/media/docs/default-source/essential-medicines/2023-eml-expert-committee/applications-for-addition-of-new-medicines/a51_ustekinumab.pdf?sfvrsn=5cc9bf75_2
17. [PDF] Application for inclusion of calcipotriol (calcipotriene) — cdn.who.int — https://cdn.who.int/media/docs/default-source/essential-medicines/2021-eml-expert-committee/applications-for-addition-of-new-medicines/a.6_calcipotriol.pdf?sfvrsn=c0e37cb4_6
18. Book of abstracts — cdn.who.int — https://cdn.who.int/media/docs/default-source/ntds/skin-ntds/first-who-global-skin-ntds-meeting-book-of-abstracts.pdf?sfvrsn=1e0b45b0_5&download=true
19. [PDF] Appendix A: Summary of evidence from surveillance | NICE — www.nice.org.uk — https://www.nice.org.uk/guidance/cg153/evidence/appendix-a-summary-of-evidence-from-surveillance-pdf-4483318862
20. [PDF] Psoriasis Guideline Consultation Comments Table - NICE — www.nice.org.uk — https://www.nice.org.uk/guidance/cg153/documents/psoriasis-consultation-comments-table2
21. Roflumilast (Zoryve) - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK624205
22. Systemic pharmacological treatments for chronic plaque psoriasis — www.cochranelibrary.com — https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011535.pub2/references
23. Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. - Abstract — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/29295598
24. Psoriatic Arthritis - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK547710

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.